	<u></u>			
•	Substitute for form 1449A/PTO	COMPLETE IF KNOWN		
	INFORMATION DISCLOSURE	Application Number	09/888,304	
AM.	OT A THE MENT DY ADDITION TO	Filing Date	June 22, 2001	
	STAREMENT BY APPLICANT	First Named Inventor	Robert K. Evans	
	APR 2 8 2008 (use as many sheets as necessary)	Group Art Unit	1633	
	(use of many sheets as necessary)	Examiner Name	Wehbe, Anne Marie Sabrina	
	Sheet 1 of 2	Attorney Docket Number	20703Y	

U.S. PATENT DOCUMENTS						
Examiner	Cite	U.S. Patent Document	Kind	Name of Patentee or Applicant	Date of Publication of Cited Document	
Initials*	No.	Number	Kind Code (if known)	of Cited Document	MM-DD-YYYY	
0						
	-					
	-					
					<u>-</u>	
					I.	
ý II						

FOREIGN PATENT DOCUMENTS						
			Foreign Patent Docume	ent		Date of Publication of
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
			<del></del>			
					•	
			<u> </u>			
			•			
Examine Signatur	er re				Date Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

î	Cubalitude for form 4.440D/DTO			COMPLETE IF KNOWN		
	NFORMATION	DIS	CLOSURE	Application Number	09/888,304	
		7 A W	DI ICANT	Filing Date	June 22, 2001	
STATEMENT BY APPLICANT				First Named Inventor	Robert K. Evans	
			,	Group Art Unit	1633	
	(use as many sheet.	s as r	iecessary)	Examiner Name	Wehbe, Anne Marie Sabrina	
Sheet	2	of	2	Attorney Docket Number	20703Y	

NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.							
	C06	Feinberg et al., "The Safety and Immunogenicity of Merck's HIV-1 gag DNA Vaccines (with or without adjuvants) in Healthy Adults", presented at AIDS Vaccine 2003, September 18-21, 2003							
	C07	Wloch et al., "Immunogenicity of a DNA-based CMV Vaccine in Humans", 43rd Annual Meeting of IDSA, October 6-9, 2005, San Francisco, pp. 238-239							
	:								

Examiner Signature		Date Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.